{"id":"889ff081-2e05-5ac0-8140-c7d2fabb91f0","stable_key":"96d9034a-2550-5f3c-b767-1767c982533c:lariciresinol-lowers-blood-glucose-in-diabetic-mice","predicate":"reduces","statement":"Three weeks of oral lariciresinol at 10 mg/kg decreased blood glucose and increased insulin on an oral glucose tolerance test in streptozotocin-treated diabetic mice.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"e3c954a0-4a20-52e9-b1d9-5f6c86b490a4","mechanism_event_label":"Three weeks of oral lariciresinol at 10 mg/kg decreased blood glucose and increased insulin on an oral glucose tolerance test in streptozotocin-treated diabetic mice.","subject":{"id":"4fcf5405-bafb-54bf-89b8-2fc11e0d9822","slug":"lariciresinol","display_name":"Lariciresinol, enantiomer unresolved","entity_type_key":"small_molecule"},"object":{"id":"9efeeb4a-fd69-534a-93f7-59f834c9eff4","slug":"stz-mouse-blood-glucose","display_name":"Blood glucose in streptozotocin-treated diabetic mice","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"e3c954a0-4a20-52e9-b1d9-5f6c86b490a4","stable_key":"96d9034a-2550-5f3c-b767-1767c982533c:lariciresinol-lowers-blood-glucose-in-diabetic-mice-event","event_type":"observed_relationship","label":"Three weeks of oral lariciresinol at 10 mg/kg decreased blood glucose and increased insulin on an oral glucose tolerance test in streptozotocin-treated diabetic mice.","description":"Three weeks of oral lariciresinol at 10 mg/kg decreased blood glucose and increased insulin on an oral glucose tolerance test in streptozotocin-treated diabetic mice.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"4fcf5405-bafb-54bf-89b8-2fc11e0d9822","slug":"lariciresinol","display_name":"Lariciresinol, enantiomer unresolved","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"9efeeb4a-fd69-534a-93f7-59f834c9eff4","slug":"stz-mouse-blood-glucose","display_name":"Blood glucose in streptozotocin-treated diabetic mice","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"b87686d5-bf72-5106-b255-c351baca4694","slug":"c2c12-glut4-translocation","display_name":"GLUT4 translocation in C2C12 myotubes","entity_type_key":"cellular_process"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"duration","value_text":"3 weeks","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Streptozotocin-treated diabetic mice","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Lariciresinol 10 mg/kg orally for 3 weeks","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Streptozotocin-induced diabetes models beta-cell destruction rather than the common human disease, and the enantiomer administered is not stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"organism","value_text":"Streptozotocin-treated diabetic mice","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Three weeks of oral lariciresinol at 10 mg/kg decreased blood glucose and increased insulin on an oral glucose tolerance test in streptozotocin-treated diabetic mice.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Lariciresinol Displays Anti-Diabetic Activity through Inhibition of α-Glucosidase and Activation and Enhancement of Insulin Signaling. (2022). https://pubmed.ncbi.nlm.nih.gov/35490401/ DOI: 10.1002/mnfr.202100910","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"Oral","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"Blood glucose, insulin and pancreatic histology","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"9ac3399b-6dff-55ae-b147-d338c55b0abd","evidence_kind":"source_excerpt","locator":"Lines 187-196","start_line":187,"end_line":196,"excerpt":"## lariciresinol-lowers-blood-glucose-in-diabetic-mice\nThree weeks of oral lariciresinol at 10 mg/kg decreased blood glucose and increased insulin on an oral glucose tolerance test in streptozotocin-treated diabetic mice.\nModel/species: Streptozotocin-treated diabetic mice\nTissue/system: Blood glucose, insulin and pancreatic histology\nExposure: Lariciresinol 10 mg/kg orally for 3 weeks\nRoute: Oral\nDuration: 3 weeks\nLimits: Streptozotocin-induced diabetes models beta-cell destruction rather than the common human disease, and the enantiomer administered is not stated.\nPrimary reference: Lariciresinol Displays Anti-Diabetic Activity through Inhibition of α-Glucosidase and Activation and Enhancement of Insulin Signaling. (2022). https://pubmed.ncbi.nlm.nih.gov/35490401/ DOI: 10.1002/mnfr.202100910\nAccess: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","model_system":"","directness":"reported_statement","verification_status":"source_derived_draft","notes":"","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"48c58761-0291-5bad-a926-75e904b2d802","stable_key":"import-96d9034a-2550-5f3c-b767-1767c982533c","title":"Lariciresinol: five molecules under one name, and the mechanisms each one carries (2026-09-22)","document_type":"imported_text","citation_label":"Original AI-assisted curation of twelve primary studies, every abstract read and all DOIs cross-checked against live PubMed metadata. Mechanism edges only, with no conclusion or claim of benefit recorded. Three author clusters account for eight of the twelve and carry shared laboratory keys. Study-specific concentrations, negative findings and limitations retained. Not publisher full text.","file_path":"","sha256":"6bf0015b7ff727b7a80d693dd18ffdd227d0e16ae45d9e85a5f81fa733edd3a4","revision_id":"219d9b0c-1a71-5e27-8d6c-7b3e77a594c6","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}